Stockscreener 앱 받기
4.75
5.32%
0.24
시장 영업 전:
4.65
-0.10
-2.11%
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Sahm
Loss Report: Will Opus Genetics Inc benefit from current market trends2026 Bull vs Bear & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Opus Genetics (IRD) 2026 proxy seeks director votes and doubling of authorized shares - Stock Titan
Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch - TipRanks
Abu Dhabi launches UAE’s first gene therapy clinical trial - TradingView
Fed Meeting: Is Opus Genetics Inc attractive for institutional investorsCPI Data & AI Driven Price Forecasts - baoquankhu1.vn
Opus Genetics (IRD) to Release Earnings on Monday - MarketBeat
Gains Report: Is Opus Genetics Inc a strong growth stock2026 Analyst Calls & Technical Pattern Based Signals - baoquankhu1.vn
OCUP SEC FilingsOcuphire Pharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Opus Genetics COO Schachle sells $19,525 in stock By Investing.com - Investing.com India
Opus Genetics, Inc. (IRD) reports Q4 loss, tops revenue estimates - MSN
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells 2,816 Shares of Stock - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells $19,041.28 in Stock - MarketBeat
Opus Genetics COO Schachle sells $19,525 in stock - Investing.com
Insider Selling: Opus Genetics (NASDAQ:IRD) CEO Sells 24,438 Shares of Stock - MarketBeat
Opus Genetics chief scientific officer sells $19k in stock - Investing.com
Opus Genetics (IRD) COO covers tax withholding via 3,719-share sale - Stock Titan
Opus Genetics (IRD) officer has 2,816 shares sold to cover tax - Stock Titan
Opus Genetics (IRD) CEO has shares sold automatically to cover RSU taxes - Stock Titan
Opus Genetics (IRD) CSO has shares sold automatically for tax withholding - Stock Titan
Aug Catalysts: Can Opus Genetics Inc reach all time highs this yearMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Oppenheimer initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Up 17.9% in February - MarketBeat
[144] Opus Genetics, Inc. SEC Filing - Stock Titan
Opus Genetics (IRD) Initiates Coverage with Outperform Rating by Oppenheimer | IRD Stock News - GuruFocus
Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD) - MarketBeat
Oppenheimer Analyst Initiates Coverage on Opus Genetics (IRD) wi - GuruFocus
Oppenheimer Initiates Opus Genetics at Outperform With $10 Price Target - marketscreener.com
There's Reason For Concern Over Opus Genetics, Inc.'s (NASDAQ:IRD) Massive 26% Price Jump - 富途牛牛
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Biotechnology company Opus Genetics Inc recently filed documents with the U.S. Securities and Exchange Commission (SEC) to officially register 7.4 million shares of common stock for secondary market resale. - Bitget
[S-3] Opus Genetics, Inc. Shelf Registration Statement | IRD SEC FilingForm S-3 - Stock Titan
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
HC Wainwright Has Negative View of Opus Genetics Q1 Earnings - MarketBeat
Lifesci Capital Forecasts Lower Earnings for Opus Genetics - MarketBeat
BTIG raises its price target on Opus Genetics, Inc. (IRD) to $12 from $7 and maintains a buy rating - MSN
Opus Genetics, Inc. 2025 Annual Report: Gene Therapy Pipeline, Clinical Progress, and Strategic Partnerships in Ophthalmology - Minichart
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Opus Genetics (NASDAQ:IRD) Given New $10.00 Price Target at Wedbush - MarketBeat
Opus Genetics (NASDAQ:IRD) Stock Price Expected to Rise, Chardan Capital Analyst Says - MarketBeat
Opus Genetics (IRD) Target Price Raised by Wedbush Analyst | IRD Stock News - GuruFocus
Chardan Capital Raises Price Target for Opus Genetics (IRD) to $11 | IRD Stock News - GuruFocus
Opus Genetics (IRD) Gets a Buy from H.C. Wainwright - The Globe and Mail
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating - Insider Monkey
Craig-Hallum Maintains Buy on Opus Genetics (IRD) March 2026 - Meyka
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA) - The Globe and Mail
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target By Investing.com - Investing.com India
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target - Investing.com Australia
1.82%
자본화:
|
볼륨(24시간):